Successful treatment of insulinoma by a single daily dose of octreotide in two elderly female patients

Endocrine Journal

Volumn 53, Issue 1, 2006, Pages 79-85

  Kishikawa, Hirofumi ^a   Okada, Yosuke ^a,b   Hirose, Akiko ^a   Tanikawa, Takahisa ^a   Kanda, Kazuko ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Advanced age; Insulinoma; Octreotide

Indexed keywords

GLUCOSE; OCTREOTIDE;

ABDOMINAL ANGIOGRAPHY; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; COMPUTER ASSISTED TOMOGRAPHY; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULINOMA; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; POSTPRANDIAL STATE; STIMULATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOGRAPHY; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULINOMA; MAGNETIC RESONANCE IMAGING; OCTREOTIDE; PANCREATIC NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645002873     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.53.79     Document Type: Article

References (26)

1. Gorden P, Comi RJ, Maton PN, Go VL (1989) Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic disease of the gut. Ann Intern Med 110: 35-50.
2. Glaser B, Rosler A, Halperin Y (1990) Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995. Isr J Med Sci 26: 16-19.
3. Von Eyben FE, Grodum E, Gjessing HJ, Hagen C, Nielsen H (1994) Metabolic remission with octreotide in patients with insulinoma. J Intern Med 235: 245-248.
4. Tanaka Y, Funahashi H, Imai T, Naruse T, Suzumura K, Oda Y (2000) The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case. Surg Today 30: 541-543.
5. Craig CE, Gallen IW (2002) Possible functional regression of insulinoma with prolonged octreotide. Postgrad Med J 78: 623-624.
6. Barrons RW (1997) Octreotide in hyperinsulinism. Ann Pharmacother 31: 239-241.
7. Gill GV, Rauf O, MacFarlane IA (1997) Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 73: 640-641.
8. Broder LE, Carter SK (1973) Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 79: 108-118.
9. Chanson P, Timsit J, Harris AG (1993) Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 25: 375-391.
10. Foxx-Orenstein A, Camilleri M, Stephens D, Burton D (2003) Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 52: 1555-1561.
11. Gyr KE, Meier R (1992) Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Metabolism 41: 17-21.
12. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Miznik H, Srikant CB (1995) The somatostatin receptor family. Life Sci 57: 1249-1265.
13. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334: 246-254.
14. Reubi JC, Landolt AM (1984) High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 59: 1148-1151.
15. Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X, Epelbaum J (2003) Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 88: 5353-5360.
16. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y (1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93: 1321-1325.
17. Oda Y, Tanaka Y, Naruse T, Sasanabe R, Tsubamoto M, Funahashi H (2002) Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today 32: 690-694.
18. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to octreotide. Endocr J 51: 227-236.
19. Del Pozo E, Neufeld M, Schluter K, Tortosa F, Clarenbach P, Bieder E, Wendel L, Nuesch E, Marbach P, Cramer H, Kerp L (1986) Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol (Copenh) 111 433-439.
20. Kutz K, Nuesch E, Rosenthaler J (1986) Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 21 (Suppl 119): 65-72.
21. Krentz AJ, Pace J, Somerville W, Clark PM, Nattrass M (1993) Effects of octreotide on circulating islet B cell products in endogenous hyperinsulinism. Postgrad Med J 69: 735-738.
22. Tanaka K, Kumagai M, Morio K, Itoh S, Hasegawa M, Watabe T, Horiuchi T, Miyabe S, Seino Y, Shimizu N (1988) Single administration of a somatostatin analogue, SMS 201-995 in healthy subjects. J Clin Therapy Med 4: 365-393 (In Japanese).
23. Kallivretakis N, Yotis A, Del Pozo E, Marbach P, Mountokalakis T, Tolis G (1985) Pharmacokinetics of SMS 201-995 in normal subjects and in patients with severe renal failure. Neuroendocrinol Lett 7: 92.
24. Koelz A, Kraenzlin M, Gyr K, Meier V, Bloom SR, Heitz P, Stalder H (1987) Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma. Gastroenterology 92: 527-531.
25. Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG (2002) Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitization and circulating antibodies to SST analogues. Eur J Endocrinol 146: 295-302.
26. Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafa MA (1989) Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh) 121: 34-40.